Results 141 to 150 of about 21,298 (206)

Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2- Women with Metastatic Breast Cancer: Results from PALCAN Study. [PDF]

Curr Oncol
Rayson D, Bertin J, Lemelin M, Tong M, Ng R, Ding P, Cheung WY, Sharma A, On PV, Feugère G, Lupichuk S.   +10 more
europepmc   +1 more source

Fulvestrant Regimen [PDF]

, 2020
openaire   +1 more source

Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive metastatic breast cancer. [PDF]

Breast Cancer Res
Shen S, Teysir J, Safonov A, Bromberg M, Chen Y, Ahmed M, Razavi P, Jhaveri K.   +7 more
europepmc   +1 more source

Cost-effectiveness analysis of inavolisib combined with palbociclib plus fulvestrant in PIK3CA-mutated HR+/Her2- advanced breast cancer in China. [PDF]

Front Pharmacol
Huang W, Li C, Huang Y, Wang C, Zhang Y, Lin Y.   +5 more
europepmc   +1 more source

Comparison Between Alpelisib Plus Endocrine Therapy and Everolimus Plus Endocrine Therapy After CDK4/6 Inhibitors Progression in Patients with <i>PIK3CA</i>-Mutant Metastatic Breast Cancer: A Single-Center Retrospective Study. [PDF]

Cancers (Basel)
Loizidis S, Michaelides D, Marcou Y, Kakouri E, Konstantinou I, Constantinidou A, Theophanous-Kitiri S, Papageorgiou E, Michailidou K, Galazi M.   +9 more
europepmc   +1 more source

Biological and computer-aided evaluation of 3-methoxy-13α-estrone-16α-diphenylphosphine oxide as a new antiestrogenic agent. [PDF]

Sci Rep
Bartha S, Germán P, Bózsity N, Puskás LG, Börzsei R, Hetényi C, Zupkó I, Mernyák E, Minorics R.   +8 more
europepmc   +1 more source

Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy [PDF]

core   +1 more source

Efficacy and Safety of Dalpiciclib in HR-Positive Advanced Breast Cancer: A Two-Center Retrospective Study. [PDF]

Cancers (Basel)
Li J, Zong Z, Zhu D, Xu X, Yan Y, Li J, Li F, Hao J.   +7 more
europepmc   +1 more source

Cold atmospheric plasma restores fulvestrant sensitivity by inhibiting CCND3 in the drug-resistant breast cancer cells. [PDF]

Sci Rep
Choi S, Jung S, Kim HW, Lee H, Jang S, Baek M, Yang SH, Choi EH, Kim SJ.   +8 more
europepmc   +1 more source

Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1. [PDF]

ESMO Open
Vaklavas C, Oliveira M, Armstrong AC, Moreno I, Twelves C, Victoria Ruiz I, Bermejo de Las Heras B, Brier T, Ciardullo C, Gibbons L, Jack T, Klinowska T, Lindemann JPO, Mathewson AM, Maudsley R, Morrow CJ, Sykes A, Baird RD.   +17 more
europepmc   +1 more source